{"disease":{"id":"acute-myeloblastic-leukemia","name":"Acute myeloblastic leukemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"chembl-chembl359744","indication_name":"Acute Myeloblastic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Acute myeloblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02085408","title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":727,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT05070208","title":"Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Acute Leukemia French Association","has_results":false},{"nct_id":"NCT07016165","title":"Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Gadjah Mada University","has_results":false},{"nct_id":"NCT05499611","title":"Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04452604","title":"Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT05696457","title":"Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT","phase":"NA","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","has_results":false},{"nct_id":"NCT05515029","title":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT01822015","title":"Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT06756152","title":"Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT01839240","title":"Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT07471789","title":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"Gyala Therapeutics","has_results":false},{"nct_id":"NCT02071901","title":"Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":31,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT07250217","title":"Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Groupe Hospitalier de la Region de Mulhouse et Sud Alsace","has_results":false},{"nct_id":"NCT01555268","title":"Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT01820624","title":"Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Paolo Caimi, MD","has_results":false},{"nct_id":"NCT02019069","title":"CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Rondeep Brar","has_results":true},{"nct_id":"NCT01801046","title":"Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT01849276","title":"Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Northwestern University","has_results":true}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}